CTSO

Cytosorbents Corporation [CTSO] Stock Forecast

Q: What is Cytosorbents Corporation stock symbol ?

Cytosorbents Corporation is a US stock, located in Princeton of Nj and trading under the symbol CTSO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CTSO Stock Summary

Earnings are expected to rise 101.53% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Currently unprofitable, and not expected to turn profitable in the coming year

CTSO has less than 1 year of cash runway

Top 10 Correlated Stocks

CTSO

In the News

10:06 11 Dec 2023 CTSO

Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript

07:00 11 Dec 2023 CTSO

CytoSorbents to Report Third Quarter 2023 Operating and Financial Results

PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2023 operating and financial results after the market close on Thursday, November 9th, 2023.

09:25 11 Dec 2023 CTSO

Cytosorbents Corporation (CTSO) Q2 2023 Results Earnings Conference Call

Cytosorbents Corporation. (NASDAQ:CTSO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Taylor Devlin - Revenue Accountant Phillip Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Interim Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christopher Cramer - Senior Vice President of Business Development Irina Kulinets - Senior Vice President of Regulatory Conference Call Participants Joshua Jennings - TD Cowen Laura Suriel - Alliance Global Partners Sean Lee - H.C.

07:00 11 Dec 2023 CTSO

CytoSorbents to Report Second Quarter 2023 Operating and Financial Results

PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2023 operating and financial results after the market close on Tuesday, August 1st, 2023. CytoSorbents' management will host a live presentation webcast and a question and answer session at 4:30PM EDT the same day.

10:11 11 Dec 2023 CTSO

Cytosorbents Corporation (CTSO) Q1 2023 Earnings Call Transcript

Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2023 Results Earnings Conference Call May 2, 2023 4:30 AM ET Company Participants Taylor Devlin - Revenue Accountant Phillip Chan - Chief Executive Officer Kathleen Bloch - Interim Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christian Steiner - Executive Vice President of Sales and Marketing Conference Call Participants Thomas Kerr - Zacks Investment Research Sean Lee - H.C. Wainwright & Co. Operator Good afternoon and welcome to the Cytosorbents First Quarter 2023 Financial and Operating Results Conference Call.

11:32 11 Dec 2023 CTSO

Cytosorbents Corporation (CTSO) Q4 2022 Earnings Call Transcript

Cytosorbents Corporation (NASDAQ:CTSO ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jodi Hoover – Manager-Clinical Administration Phillip Chan – Chief Executive Officer Irina Kulinets – Senior Vice President-Global Regulatory Kathleen Bloch – Chief Financial Officer Efthymios Deliargyris – Chief Medical Officer Vincent Capponi – President and Chief Operating Officer Christian Steiner – Executive Vice President-Sales and Marketing and Managing Director-CytoSorbents Europe GmbH Conference Call Participants Mike Sarcone – Jefferies Josh Jennings – TD Cowen Sean Lee – H.C. Wainwright Tom Kerr – Zacks Investment Research Operator Good afternoon, and welcome to the Cytosorbents Fourth Quarter and Full Year 2022 Financial and Operating Results Conference Call.

07:00 11 Dec 2023 CTSO

CytoSorbents to Report Fiscal 2022 Operating and Financial Results

MONMOUTH JUNCTION, N.J. , Feb. 24, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2022 financial results on Thursday, March 9, 2023 at 4:30PM EST.

06:20 11 Dec 2023 CTSO

CytoSorbents Corporation (CTSO) Q3 2022 Earnings Call Transcript

CytoSorbents Corporation (NASDAQ:CTSO ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Michelle Almonte - Executive Assistant to CEO Phillip Chan - Chief Executive Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - EVP of Sales and Marketing and Managing Director of CytoSorbents Europe GmbH Efthymios Deliargyris - Chief Medical Officer Vincent Capponi - Chief Operating Officer and President Christopher Cramer - VP of Business Development Conference Call Participants Zachary Weiner - Jefferies Sean Lee - H.C. Wainwright Operator Good day, and welcome to the CytoSorbents Corporation Third Quarter 2022 Earnings Conference Call.

09:49 11 Dec 2023 CTSO

CytoSorbents (CTSO) Reports Q3 Loss, Misses Revenue Estimates

CytoSorbents (CTSO) delivered earnings and revenue surprises of -75% and 9.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

07:00 11 Dec 2023 CTSO

CytoSorbents to Report Third Quarter 2022 Operating and Financial Results

PRINCETON, N.J. , Oct. 27, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2022 operating and financial results after the market close on Thursday, November 3, 2022.

CTSO Financial details

Company Rating

Buy

Market Cap

56.88M

Income

-22.87M

Revenue

31.38M

Book val./share

0.42

Cash/share

0.19

Dividend

Dividend %

Employees

198

Optionable

Shortable

Yes

Earnings

07 Mar 2024

P/E

-2.48

Forward P/E

-2.92

PEG

2.81

P/S

1.81

P/B

3.07

P/C

6.45

P/FCF

-2.64

Quick Ratio

1.21

Current Ratio

1.61

Debt / Equity

0.97

LT Debt / Equity

0.92

EPS (TTM)

-0.52

EPS next Y

-0.42

EPS next Q

-0.1

EPS this Y

31.58%

EPS next Y

-19.18%

EPS next 5Y

-67.93%

EPS last 5Y

6.02%

Revenue last 5Y

7.71%

Revenue Q/Q

-3.94%

EPS Q/Q

50%

SMA20

SMA50

-50%

SMA100

-75%

Inst Own

25.28%

Inst Trans

0.73%

ROA

-48%

ROE

-86%

ROC

-0.79%

Gross Margin

55%

Oper. Margin

-90%

Profit Margin

-73%

Payout

Shs Outstand

44.44M

Shs Float

38.46M

Target Price

52W Range

1.03-4.59

52W High

-69.38%

52W Low

+22.5%

RSI

Rel Volume

0.74

Avg Volume

98.53K

Volume

72.79K

Perf Week

4.7%

Perf Month

-15.52%

Perf Quarter

-65.4%

Perf Half Y

-63.21%

Beta

0.67

Volatility

0.05%, 0.1%

Prev Close

-4.3%

Price

1.225

Change

-12.5%

CTSO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.66	0.71	1.02	0.93	0.67
Net income per share	-0.56	-0.6	-0.2	-0.57	-0.75
Operating cash flow per share	-0.35	-0.52	-0.14	-0.32	-0.65
Free cash flow per share	-0.4	-0.57	-0.19	-0.42	-0.8
Cash per share	0.73	0.38	1.84	1.2	0.51
Book value per share	0.55	0.11	2.04	1.44	0.81
Tangible book value per share	0.47	0	1.93	1.33	0.71
Share holders equity per share	0.55	0.11	2.04	1.44	0.81
Interest debt per share	0.37	0.53	0.06	0.32	0.42
Market cap	248.21M	124.18M	309.39M	181.67M	67.54M
Enterprise value	235.78M	128.07M	238.99M	143.36M	63.64M
P/E ratio	-14.42	-6.45	-39.48	-7.4	-2.06
Price to sales ratio	12.26	5.45	7.84	4.53	2.3
POCF ratio	-22.9	-7.41	-55.12	-12.97	-2.39
PFCF ratio	-20.08	-6.79	-42.44	-9.93	-1.95
P/B Ratio	14.66	36.33	3.91	2.9	1.91
PTB ratio	14.66	36.33	3.91	2.9	1.91
EV to sales	11.64	5.63	6.06	3.57	2.17
Enterprise value over EBITDA	-15.52	-6.75	-23.05	-7.11	-2.19
EV to operating cash flow	-21.75	-7.64	-42.58	-10.24	-2.25
EV to free cash flow	-19.08	-7.01	-32.79	-7.84	-1.83
Earnings yield	-0.07	-0.16	-0.03	-0.14	-0.49
Free cash flow yield	-0.05	-0.15	-0.02	-0.1	-0.51
Debt to equity	0.59	4.72	0.01	0.22	0.52
Debt to assets	0.3	0.59	0.01	0.15	0.29
Net debt to EBITDA	0.82	-0.21	6.79	1.9	0.13
Current ratio	4.32	2.1	8.12	4.7	3.48
Interest coverage	-10.67	-18.36	-8.63	0	-237.73
Income quality	0.63	0.87	0.72	0.57	0.86
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.13	1.07	0.8	0.96	1.26
Research and developement to revenue	0.38	0.53	0.22	0.41	0.51
Intangibles to total assets	0.08	0.12	0.05	0.05	0.07
Capex to operating cash flow	0.14	0.09	0.3	0.31	0.23
Capex to revenue	-0.08	-0.07	-0.04	-0.11	-0.22
Capex to depreciation	-3.89	-2.61	-2.54	-3.79	-5.7
Stock based compensation to revenue	0.27	0.12	0.12	0.15	0.13
Graham number	2.64	1.19	3.04	4.29	3.71
ROIC	-0.56	-0.87	-0.11	-0.24	-0.46
Return on tangible assets	-0.57	-0.8	-0.09	-0.29	-0.56
Graham Net	0.32	-0.23	1.7	0.71	0.01
Working capital	21.73M	10.97M	72.3M	50.61M	24.05M
Tangible asset value	14.31M	56.59K	74.99M	57.88M	30.98M
Net current asset value	12.45M	-3.06M	71.72M	37.36M	5.9M
Invested capital	0.59	4.72	0.01	0.22	0.52
Average receivables	3.07M	4.21M	4.81M	4.84M	5.09M
Average payables	1.77M	2M	1.94M	2.32M	2.23M
Average inventory	814.4K	1.47M	2.39M	3.72M	4.11M
Days sales outstanding	71.07	71.62	47.73	41.16	70.43
Days payables outstanding	95.79	101.06	60.6	92.67	43.28
Days of inventory on hand	40.6	104.78	88.3	157.46	90.52
Receivables turnover	5.14	5.1	7.65	8.87	5.18
Payables turnover	3.81	3.61	6.02	3.94	8.43
Inventory turnover	8.99	3.48	4.13	2.32	4.03
ROE	-1.02	-5.64	-0.1	-0.39	-0.93
Capex per share	-0.05	-0.05	-0.04	-0.1	-0.15

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.15	0.2	0.18	0.18	0.17
Net income per share	-0.28	-0.02	-0.15	-0.14	-0.21
Operating cash flow per share	-0.15	-0.14	-0.07	-0.16	-0.12
Free cash flow per share	-0.17	-0.14	-0.09	-0.15	-0.12
Cash per share	0.52	0.57	0.44	0.3	0.19
Book value per share	0.9	0.91	0.66	0.55	0.42
Tangible book value per share	0.9	0.8	0.66	0.55	0.42
Share holders equity per share	0.9	0.91	0.66	0.55	0.42
Interest debt per share	0.31	0.47	0.4	0.41	0.41
Market cap	59.31M	60.17M	147.19M	158.02M	83.42M
Enterprise value	50.14M	56.28M	146.33M	162.98M	93.11M
P/E ratio	-1.22	-19.63	-5.44	-6.42	-2.27
Price to sales ratio	9.18	7.87	18.61	19.57	10.76
POCF ratio	-8.81	-11.27	-47.36	-22.79	-16.02
PFCF ratio	-7.96	-10.85	-38.83	-23.5	-15.27
P/B Ratio	1.52	1.7	5.08	6.56	4.51
PTB ratio	1.52	1.7	5.08	6.56	4.51
EV to sales	7.76	7.36	18.5	20.19	12.01
Enterprise value over EBITDA	-9.1	-5.31	-17.11	-25.01	-12.67
EV to operating cash flow	-7.44	-10.54	-47.08	-23.51	-17.88
EV to free cash flow	-6.73	-10.15	-38.6	-24.24	-17.04
Earnings yield	-0.2	-0.01	-0.05	-0.04	-0.11
Free cash flow yield	-0.13	-0.09	-0.03	-0.04	-0.07
Debt to equity	0.34	0.52	0.63	0.75	0.97
Debt to assets	0.21	0.29	0.32	0.35	0.38
Net debt to EBITDA	1.66	0.37	0.1	-0.76	-1.32
Current ratio	3.2	3.48	2.7	2.28	1.61
Interest coverage	-192.49	-118.26	13.94	743.59	-216.18
Income quality	0.55	6.97	0.42	1.13	0.57
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.45	1.14	1.15	1.1	1.19
Research and developement to revenue	0.51	0.45	0.53	0.45	0.48
Intangibles to total assets	0	0.07	0	0	0
Capex to operating cash flow	0.11	0.04	0.22	-0.03	0.05
Capex to revenue	-0.11	-0.03	-0.09	0.03	-0.03
Capex to depreciation	-2.58	-0.74	-2.17	0.46	-0.56
Stock based compensation to revenue	0.21	0.14	0.14	0.03	0.17
Graham number	2.37	0.64	1.52	1.31	1.39
ROIC	-0.14	-0.04	-0.12	-0.11	-0.14
Return on tangible assets	-0.2	-0.01	-0.12	-0.12	-0.19
Graham Net	0.11	0.01	-0.1	-0.2	-0.33
Working capital	22.26M	24.05M	17.73M	13.29M	7.29M
Tangible asset value	39.14M	30.98M	28.96M	24.09M	18.51M
Net current asset value	9.25M	5.9M	-343K	-4.71M	-9.8M
Invested capital	0.34	0.52	0.63	0.75	0.97
Average receivables	5.07M	5.31M	5.6M	6.28M	6.6M
Average payables	2.24M	2.43M	2.75M	2.92M	3.14M
Average inventory	4.26M	3.5M	2.59M	1.89M	2.51M
Days sales outstanding	69.09	66.72	62.9	78.32	71.72
Days payables outstanding	47.02	62.07	67.49	75.02	96.69
Days of inventory on hand	70.93	85.74	38.89	54.12	83.62
Receivables turnover	1.3	1.35	1.43	1.15	1.25
Payables turnover	1.91	1.45	1.33	1.2	0.93
Inventory turnover	1.27	1.05	2.31	1.66	1.08
ROE	-0.31	-0.02	-0.23	-0.26	-0.5
Capex per share	-0.02	-0.01	-0.02	0	-0.01

CTSO Frequently Asked Questions

What is Cytosorbents Corporation stock symbol ?

Cytosorbents Corporation is a US stock , located in Princeton of Nj and trading under the symbol CTSO

What is Cytosorbents Corporation stock quote today ?

Cytosorbents Corporation stock price is $1.225 today.

Is Cytosorbents Corporation stock public?

Yes, Cytosorbents Corporation is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 98.53K
Market Capitalization 56.88M
Employee 198
CEO Dr. Phillip P. Chan M.D., Ph.D.
Headquarters Princeton,NJ,US
IPO Date 2006-08-08
Website https://www.cytosorbents.com

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.